Ocular Regenerative Medicine

Canadian Ocular Regenerative Medicine Society

Sunday June 18, 1045—1215
Room 522ABC

Learning objectives

At the end of this session, participants will be able to:

• Explain how limbal stem cells are expanded ex vivo and transplanted
• Assess the efficacy of cell injection and regenerative therapy in endothelial disease
• Assess the efficacy and state of the art of biosynthesis substitutes in treating corneal disease

---

GUEST SPEAKERS Jodhbir S. Mehta, Bsc (Hons.), MBBS, FRCOphth, FRCS (Ed.), FAMS Graziella Pellegrini, MD MODERATORS Isabelle Brunette, MD Allan Slomovic, MSc, MD

FACULTY Brian Ballios, MD May Griffith, MD Jacky Slomovic, BSc

---

Agenda

1045	Regenerative medicine of the ocular surface: What is missing • Graziella Pellegrini
1100	Assessing the efficacy of cell injection and tissue engineered endothelial keratoplasty for endothelial disease • Jodhbir S. Mehta
1110	The first stem cell treatment EU approved • Graziella Pellegrini
1120	Regenerative therapy in Fuchs’ corneal dystrophy: • Jodhbir S. Mehta
1130	National ocular stem cell registry • Brian Ballios, Isabelle Brunette, Jacky Slomovic, Allan Slomovic
1145	Biosynthetic corneal substitutes: Has it become a reality? • May Griffith
1200	Canadian Ocular Regenerative Medicine Society business meeting
1215	Adjourn